Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
Abstract Objective Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It has a wide range of clinical applications in various cancers and retinal diseases. The drugs entered the Chinese market by a large margin in 2017, and the user population changed to some extent. Th...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Journal of Pharmaceutical Health Care and Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40780-023-00314-w |